AstraZeneca to add CAR T-cell therapy to pipeline with Gracell buy
AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting…
Myeloma
Darzalex Faspro combo benefits patients new to MM and transplant
Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…
Elrexfio approved for hard-to-treat multiple myeloma patients in Europe
The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior…
New cases of myeloma rose in US, mostly in young Hispanic women
A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the…
Blenrep works better than Darzalex as early therapy, trial data show
When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant …
FDA delays its decision on earlier Abecma treatment for RRMM
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
1st patient dosed in Phase 1 trial of triple-target treatment ISB 2001
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos…
Foundation awards $21M in grants for multicenter myeloma research
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly…
Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
Survival rates by race found similar with Abecma in myeloma study
Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but…
